An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.
Also called NCT01064414
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 272 participants
- Registry
-
NCT01064414
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Brazil, Canada, France, Germany, India, Latvia, Malaysia, Mexico, New Zealand, Poland, Romania, Russia, South Africa, South Korea, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01064414. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2013-05-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Renal Insufficiency
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01064414- Content hash
2974a5172b238b16ae4aa032a24a4f34135e20a92cbe63b3857f783afbbeb756